Abaloparatide vs Teriparatide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Abaloparatide (Tymlos) is a synthetic 34-amino acid analogue of parathyroid hormone-related protein (PTHrP 1-34), FDA-approved in 2017 for postmenopausal osteoporosis at high fracture risk. Unlike teriparatide (which is PTH 1-34), abaloparatide is derived from PTHrP and incorpora...
Calculate Abaloparatide dose →Teriparatide is the recombinant N-terminal 34-amino acid fragment of human parathyroid hormone (PTH 1-34), FDA-approved since 2002 as the first anabolic bone therapy for osteoporosis. While continuous PTH elevation (as in hyperparathyroidism) causes bone resorption, intermittent ...
Calculate Teriparatide dose →| Parameter | Abaloparatide | Teriparatide |
|---|---|---|
| Category | Bone Anabolic Peptide | Bone Anabolic Peptide |
| Research | FDA Approved | FDA Approved |
| Half-Life | ~1 hour SC | ~1 hour SC |
| Typical Dose | 80 mcg SC once daily | 20 mcg SC once daily |
| Frequency | Once daily SC | Once daily SC |
| Route | SC injection (once daily) | SC injection (once daily) |
| FDA Status | FDA approved 2017 for postmenopausal osteoporosis at high fracture risk | FDA approved for osteoporosis (postmenopausal women, men, glucocorticoid-induced) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.